GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (STU:EU6) » Definitions » Scaled Net Operating Assets

PDS Biotechnology (STU:EU6) Scaled Net Operating Assets : -0.05 (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is PDS Biotechnology Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PDS Biotechnology's operating assets for the quarter that ended in Sep. 2024 was €2.43 Mil. PDS Biotechnology's operating liabilities for the quarter that ended in Sep. 2024 was €5.21 Mil. PDS Biotechnology's Total Assets for the quarter that ended in Jun. 2024 was €56.20 Mil. Therefore, PDS Biotechnology's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was -0.05.


PDS Biotechnology Scaled Net Operating Assets Historical Data

The historical data trend for PDS Biotechnology's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Scaled Net Operating Assets Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.07 -0.05 -0.10 -0.08

PDS Biotechnology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.11 -0.09 -0.04 -0.05

Competitive Comparison of PDS Biotechnology's Scaled Net Operating Assets

For the Biotechnology subindustry, PDS Biotechnology's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Scaled Net Operating Assets falls into.



PDS Biotechnology Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PDS Biotechnology's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(2.595-8.627)/72.696
=-0.08

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=54.461 - 51.866
=2.595

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=30.499 - 18 - 3.872
=8.627

PDS Biotechnology's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(2.432-5.207)/56.201
=-0.05

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=47.258 - 44.826
=2.432

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=27.435 - 10.911 - 11.317
=5.207

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDS Biotechnology Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology Business Description

Traded in Other Exchanges
Address
303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

PDS Biotechnology Headlines

No Headlines